
1. virology. 2012 jun 5;427(2):158-65. doi: 10.1016/j.virol.2012.02.006. epub 2012
mar 16.

v3 determinants hiv-1 escape ccr5 inhibitors maraviroc and
vicriviroc.

berro r(1), klasse pj, jakobsen mr, gorry pr, moore jp, sanders rw.

author information: 
(1)department microbiology immunology, weill medical college cornell
university, new york, ny 10065, usa.

erratum in
    virology. 2012 jun 20;428(1):76. jakobsen, martin r [added]; gorry, paul r
[added].

hiv-1 develops resistance ccr5 antagonists maraviroc (mvc) and
vicriviroc (vvc) vitro vivo, changes arising the
gp120 v3 region. compounds bind hydrophobic cavity ccr5 in
subtly different ways. here, investigated v3 sequence changes most
associated mvc vvc resistance affect interaction
between gp120 ccr5 nt. found vvc- mvc-selected amino acid
changes map different v3 locations involve residues interact the
ccr5 nt different ways. changes vvc-selected, mvc-selected,
variants often involve charged residues. although overall v3 charge tends not
to change, introduction removal charged residues specific positions 
affects local electrostatic potential could structural and
functional implications. summary, vvc mvc trigger evolution of
distinct hiv-1 resistance patterns v3.

copyright â© 2012 elsevier inc. rights reserved.

doi: 10.1016/j.virol.2012.02.006 
pmcid: pmc3320651
pmid: 22424737  [indexed medline]

